Childhood brain tumours,early infections and immune stimulation: A pooled analysis of the ESCALE and ESTELLE case-control studies (SFCE,France) |
| |
| Institution: | 1. UMRS 1153, INSERM, Université Paris-Descartes, Université Sorbonne-Paris-Cité, CRESS-EPICEA Epidémiologie des cancers de l’enfant et de l’adolescent, Paris, France;2. Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland;3. RNCE – National Registry of Childhood Cancers, Inserm, Villejuif and CHU de Nancy, France;4. Gustave Roussy, Département de cancérologie de l’enfant et de l’adolescent, Villejuif, France;5. Unité d’ Hémato-Immuno-Oncologie pédiatrique, Pôle Pédiatriqe, CHU Toulouse, France;6. Pediatric Oncology Unit, Oscar Lambret Comprehensive Cancer Center, Lille, France;7. Institut d’hématologie et d’oncologie pédiatrique, IHOPe, Centre Léon Bérard, Lyon, France;8. Unité immuno-hémato-oncopédiatrie, CHU d’Angers, Angers, France;9. Clinique de pédiatrie, Hôpital Couple Enfant, CHU Grenoble-Alpes, Grenoble, France;10. Oncology Center SIREDO (Care Innovation Research in Children, Adolescents and Young Adults Cancer), Institut Curie and Université Paris Descartes, Paris, France;11. Service de neurochirurgie pédiatrique, Hôpital Necker-Enfants malades, Université Paris Descartes, Sorbonne Paris Cité, Paris, France;12. Service d’onco-hématologie pédiatrique, Hôpital Pellegrin Tripode, Bordeaux, France;1. Department of Urology, University of Oklahoma HSC, Oklahoma City, OK, United States;2. Department of Health and Exercise Science, University of Oklahoma, Norman, OK, United States;1. Department of Surgical Sciences, Uppsala University, Uppsala, Sweden;2. Regional Cancer Center Sweden, Uppsala, Sweden;3. Department of Surgery, Skåne University Hospital, Lund, Sweden;4. Division of Surgery, Center for Digestive Diseases, Karolinska University Hospital and Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden;1. Golestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran;2. Hyrcania Cancer Research Center, Golestan University of Medical Sciences, Gorgan, Iran;3. Deputy of Public Health, Golestan University of Medical Sciences, Gorgan, Iran;4. Deputy of Research and Technology, Golestan University of Medical Sciences, Gorgan, Iran;5. Rheumatology Research Center, Golestan University of Medical Sciences, Gorgan, Iran;6. Department of Pathology, Sayyad Shirazi Hospital, Golestan University of Medical Sciences, Gorgan, Iran;7. Death Registry Unit, Deputy of Public Health, Golestan University of Medical Sciences, Gorgan, Iran;8. Deputy of Treatment, Golestan University of Medical Sciences, Gorgan, Iran;9. Statistics and Information Technology Office, Golestan University of Medical Sciences, Gorgan, Iran;10. Shafa Radiotherapy Center, 5 Azar Hospital, Gorgan, Iran;11. Digestive Oncology Research Center, Digestive Disease Research Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran;12. Cancer Surveillance Section, International Agency for Research on Cancer, Lyon, France;1. Department of Haematology and Central Haematology Laboratory, Inselspital, Bern University Hospital, University of Bern, Switzerland;2. Department for BioMedical Research, Inselspital, Bern University Hospital, University of Bern, Switzerland;3. Foundation National Institute for Cancer Epidemiology and Registration (NICER) c/o University of Zurich, Switzerland;4. Divisions of Hematology, Department of Medicine, University Hospital Basel, Switzerland;5. Haematology, University and University Hospital Zurich, Switzerland;6. Division of Haematology and Central Haematology Laboratory, Cantonal Hospital Lucerne, Switzerland;7. Department of Haemato-Oncology, Cantonal Hospital Fribourg, Switzerland;8. Division of Haematology and Transfusion Medicine, Cantonal Hospital Aarau, Switzerland;9. Clinic for Haematology and Oncology,Cantonal Hospital St. Gallen, Switzerland;10. Service and Central Laboratory of Haematology, Centre Hospitalier Universitaire Vaudois, Lausanne University Hospital, Switzerland;11. Department of Oncology, Division of Hematology, Geneva University Hospitals and Faculty of Medicine, University of Geneva, Switzerland;12. Clinic of Haematology, Oncology Institute of Southern Switzerland, Switzerland;1. Departments of Clinical Pharmacy and of Medicine, University of California, 3333 California Street, Suite 420, San Francisco, CA, 94143-0613, USA;2. Department of Clinical Pharmacy, University of California, 3333 California Street, San Francisco, CA, 94143-0613, USA;3. San Francisco Department of Public Health, 25 Van Ness Avenue, Suite 500, San Francisco, CA, 94102-6012, USA;1. Department of Epidemiology, Fielding School of Public Health, University of California, CA, USA;2. Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA;3. Division of Pediatric Hematology/Oncology, Department of Pediatrics, David Geffen School of Medicine, University of California, Los Angeles, CA, USA |
| |
| Abstract: | BackgroundFew studies have investigated whether early infections and factors potentially related to early immune stimulation might be involved in the aetiology of childhood brain tumours (CBT). In this study, we investigated the associations between CBT with early day-care attendance, history of early common infections, atopic conditions (asthma/wheezing, eczema, allergic rhinitis), early farm residence/visits and contact with animals.MethodsWe pooled data from two nationwide French case-control studies, the ESCALE and ESTELLE studies. Children with a CBT diagnosed between 1 and 14 years of age were identified directly from the French National Registry of Childhood Cancers, while population controls were recruited from telephone subscribers. Odds-ratios (OR) and 95% confidence intervals (CI) were estimated using logistic regression adjusted for potential confounders.ResultsThe analyses included 469 cases and 2719 controls. We found no association between attending a day-care centre (OR: 0.9, 95%CI: 0.7–1.2) or having had repeated common infections (OR: 0.9, 95%CI: 0.7–1.2) in the first year of life and the risk of CBT. There was also no association with a history of asthma/wheezing (OR: 0.8, 95%CI: 0.56–1.1). Farm visits (OR: 0.6, 95%CI: 0.5–0.8) as well as contact with pets (OR: 0.8, 95%CI: 0.6–1.0) in the first year of life were inversely associated with CBT.ConclusionsOur findings suggest a protective effect of early farm visits and contact with pets, but not with other markers of early immune stimulation. This might be related to immune stimulation but needs further investigation. |
| |
| Keywords: | Children Central nervous system tumours Brain tumours Risk factors Day-care Infections Atopy Allergies Farm Animals Case control study |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
